ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Article
- Plasma Profile of Brain-Derived Tau After Ischemic Stroke.European journal of neurology · 2026Observational
- Tau pathology in epilepsy: emerging mechanisms and translational opportunities.Brain : a journal of neurology · 2026Review
- Astrocyte autophagy-pyroptosis crosstalk in Alzheimer's: insights from knowledge graphs.BMC neurology · 2026Article
- Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay.Scientific reports · 2026Article
- Review
- Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay.medRxiv : the preprint server for health sciences · 2025Article
- Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease.Neurology · 2025Observational
- Brain-Derived Tau as an Outcome Marker in Guillain-Barré Syndrome: A Retrospective Cohort Study.European journal of neurology · 2025Article
- Plasma brain-derived tau correlates with cerebral infarct volume.Journal of internal medicine · 2025Article
- Effect of blood collection tube containing protease inhibitors on the pre-analytical stability of Alzheimer's disease plasma biomarkers.Journal of neurochemistry · 2024Article
- Novel diagnostic and prognostic approach for rapidly progressive dementias: Indicators based on amyloid/tau/neurodegeneration (ATN) framework.CNS neuroscience & therapeutics · 2024Article
- Advances in Alzheimer's Disease Biomarkers.Current Alzheimer research · 2024Review
- Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients.Alzheimer's & dementia (New York, N. Y.)Article
- Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt-Jakob disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 5 countries.
Funding
Abstract
introductionRapidly progressive dementias (RPDs) are a group of neurological disorders characterized by a rapid cognitive decline. The diagnostic value of blood-based biomarkers for Alzheimer's disease (AD) in RPD has not been fully explored.
methodsWe measured plasma brain-derived tau (BD-tau) and p-tau181 in 11 controls, 15 AD patients, and 33 with RPD, of which 19 were Creutzfeldt-Jakob disease (CJD).
resultsPlasma BD-tau differentiated AD from RPD and controls (p = 0.002 and p = 0.03, respectively), while plasma and cerebrospinal fluid (CSF) p-tau181 distinguished AD from RPD (p < 0.001) but not controls from RPD (p > 0.05). The correlation of CSF t-tau with plasma BD-tau was stronger (r = 0.78, p < 0.001) than the correlation of CSF and plasma p-tau181 (r = 0.26, p = 0.04). The ratio BD-tau/p-tau181 performed equivalently to the CSF t-tau/p-tau181 ratio, differentiating AD from CJD (p < 0.0001). DISCUSSION: Plasma BD-tau and p-tau181 mimic their corresponding cerebrospinal fluid (CSF) markers. P-tau significantly increased in AD but not in RPD. Plasma BD-tau, like CSF t-tau, increases according to neurodegeneration intensity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.